31 results
Thumbnail

D1.281 - Development of a Peanut-Specific Human Mast Cell Assay for Screening Probiotics and other Nutritional Components with Anti-Allergic Potential

Thumbnail

D1.284 - Eosinophilic Esophagitis Before and After Milk Oral Immunotherapy in Children with Food Allergy: A Case Series Including the Eosinophil-to-Lymphocyte Ratio

Thumbnail

D1.278 - Dragon fruit Allergy: A Case of Cross-Reactivity and Dietary Risks

Thumbnail

D1.279 - Oral Immune Tolerance Induction Therapy with IFN-gamma in children with rice allergy

Thumbnail

D1.280 - Microbiome Signatures Associated with Food Allergy Resolution in Children

Thumbnail

D1.283 - Endolysosomal degradation of major peanut allergens revealed distinct degradation kinetics and T cell epitope regions

Thumbnail

D1.285 - Novel food supplement containing a combination of postbiotics and plant-derived compounds regulates epithelial barrier integrity and immune response in human enterocytes

Thumbnail

D1.286 - Allergenic Protein Profiling in a Patient with Long-standing Nut-Induced Anaphylaxis

Thumbnail

D1.287 - Polysensitization to Seed Storage Proteins, LTPs and Profilin in a Patient With Anaphylaxis After Consumption of Pesto Sauce

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut